Bahrainwala Jehan, Berns Jeffrey S
Renal, Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Renal, Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Semin Nephrol. 2016 Mar;36(2):94-8. doi: 10.1016/j.semnephrol.2016.02.002.
Anemia is a common and clinically important consequence of chronic kidney disease (CKD). It is most commonly a result of decreased erythropoietin production by the kidneys and/or iron deficiency. Deciding on the appropriate treatment for anemia associated with CKD with iron replacement and erythropoietic-stimulating agents requires an ability to accurately diagnose iron-deficiency anemia. However, the diagnosis of iron-deficiency anemia in CKD patients is complicated by the relatively poor predictive ability of easily obtained routine serum iron indices (eg, ferritin and transferrin saturation) and more invasive gold standard measures of iron deficiency (eg, bone marrow iron stores) or erythropoietic response to supplemental iron. In this review, we discuss the diagnostic utility of currently used serum iron indices and emerging alternative markers of iron stores.
贫血是慢性肾脏病(CKD)常见且具有临床重要性的后果。其最常见的原因是肾脏促红细胞生成素生成减少和/或缺铁。决定使用铁剂替代和促红细胞生成刺激剂对与CKD相关的贫血进行适当治疗,需要具备准确诊断缺铁性贫血的能力。然而,CKD患者缺铁性贫血的诊断较为复杂,因为易于获得的常规血清铁指标(如铁蛋白和转铁蛋白饱和度)的预测能力相对较差,而缺铁的更具侵入性的金标准检测方法(如骨髓铁储存)或对补充铁剂的促红细胞生成反应也是如此。在本综述中,我们讨论了目前使用的血清铁指标以及新出现的铁储存替代标志物的诊断效用。